老年人中最常见的神经退行性疾病和痴呆的主要原因是阿尔茨海默病。目前可用的痴呆症药物仅有助于缓解认知缺陷的症状,并具有一些负面影响。当前研究的目标是评估姜黄素和辅酶Q10这两种草药的作用,无论是单独还是组合,在学习和记忆方面,然后再将它们与行业标准药物进行比较。在我们的研究中总共使用了42只成年健康Wistar大鼠。在这个实验中,大鼠每日给予2.5mg/kg体重的氢溴酸东莨菪碱7天以诱发阿尔茨海默病。第八天,进行了行为测试。测试后,在接下来的21天内,每天给予东pol碱和测试药物。在第29天和第30天,再次进行行为测试,然后动物被宰杀。产生脑匀浆以估计分子和生化标志物。姜黄素表现出剂量-反应关系,较高剂量(200mg/kgb.w.p.o.)比较低剂量(100mg/kgb.w.p.o.)更有效。类似于更大剂量的姜黄素,辅酶Q10(200mg/kgb.w.p.o.)也被发现改善记忆和学习。较高剂量的姜黄素和辅酶Q10具有更明显和有意义的作用。乙酰胆碱酯酶和TNF水平在东莨菪碱诱导的记忆障碍中增加,但是这些效果被测试药物恢复了,并通过联合治疗得到改善。这些结果与普通药物美金刚相当。因此,我们可以从我们的结果推断,在阿尔茨海默病动物模型中,高剂量的姜黄素及其与辅酶Q10(200mg/kgb.w.p.o.)的组合对认知障碍有显著影响,可以单独使用或作为该疾病的附加疗法。
The most frequent neurodegenerative illness among senior people and the main cause of dementia is Alzheimer\'s disease. The present dementia medications available only help with the symptoms of cognitive deficits and have several negative effects. The current study\'s goal is to assess the effects of curcumin and coenzyme Q10, two herbal medicines, both separately and in combination, on learning and memory before comparing them to the industry standard drug. A total of 42 adult healthy Wistar rats were used in our study. In this experiment, rats were given daily doses of 2.5 mg/kg of body weight of scopolamine hydrobromide for 7 days to induce Alzheimer\'s disease. On the eighth day, behavioural testing was conducted. Following testing, scopolamine and the test medications were given daily for the following 21 days. On days 29 and 30, behavioural testing was conducted once more, and then animals were slaughtered. Brain homogenate was produced for the estimation of molecular and biochemical markers. Curcumin has demonstrated a dose-response relationship, with a higher dose (200 mg/kg b.w. p.o.) being more effective than a lower dose (100 mg/kg b.w. p.o.). Similar to the greater dose of curcumin, coenzyme Q10 (200 mg/kg b.w. p.o.) has also been found to improve memory and learning. Higher doses of curcumin and coenzyme Q10 had more pronounced and meaningful effects. Acetylcholinesterase and TNF levels increased in scopolamine-induced memory impairment, but these effects were restored by the test medications, and improved by the combined therapy. These outcomes are comparable to those of the common medication memantine. As a result, we may infer from our results that curcumin at higher doses and its combination with coenzyme Q10 (200 mg/kg b.w. p.o.) have a significant impact on cognitive impairment in animal models of Alzheimer\'s disease and can be utilised alone or as an add-on therapy for the condition.